Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 195

1.

Updates on Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi LS, Ong LM, Irish AB; FAVOURED study team.

Nephrology (Carlton). 2016 May 18. doi: 10.1111/nep.12823. [Epub ahead of print] No abstract available.

PMID:
27188542
2.

Association between Serum Hepcidin-25 and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial.

Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group.

Nephrology (Carlton). 2016 May 12. doi: 10.1111/nep.12815. [Epub ahead of print]

PMID:
27171136
3.

Long-term outcomes of end-stage kidney disease for patients with lupus nephritis.

Zhang L, Lee G, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW.

Kidney Int. 2016 Jun;89(6):1337-45. doi: 10.1016/j.kint.2016.02.014. Epub 2016 Apr 8.

PMID:
27165824
4.

The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.

Badve SV, Palmer SC, Strippoli GF, Roberts MA, Teixeira-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, Johnson DW.

Am J Kidney Dis. 2016 Apr 30. pii: S0272-6386(16)30024-5. doi: 10.1053/j.ajkd.2016.03.418. [Epub ahead of print]

PMID:
27138469
5.

Focus on peritoneal dialysis training: working to decrease peritonitis rates.

Zhang L, Hawley CM, Johnson DW.

Nephrol Dial Transplant. 2016 Feb;31(2):214-22. doi: 10.1093/ndt/gfu403. Epub 2015 Jan 28. Review.

PMID:
26908816
6.

CENTER-SPECIFIC FACTORS ASSOCIATED WITH PERITONITIS RISK-A MULTI-CENTER REGISTRY ANALYSIS.

Nadeau-Fredette AC, Johnson DW, Hawley CM, Pascoe EM, Cho Y, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP.

Perit Dial Int. 2016 Jan 13. pii: pdi.2015.00146. [Epub ahead of print]

PMID:
26764341
7.

The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.

Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group.

Am J Kidney Dis. 2016 Jun;67(6):902-11. doi: 10.1053/j.ajkd.2015.10.029. Epub 2015 Dec 22.

PMID:
26717861
8.

Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice.

Fahim MA, Hayen AD, Horvath AR, Dimeski G, Coburn A, Tan KS, Johnson DW, Craig JC, Campbell SB, Hawley CM.

Clin Chem Lab Med. 2016 Apr 1;54(5):e149-50. doi: 10.1515/cclm-2015-0998. No abstract available.

PMID:
26562041
9.

Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations.

Marshall MR, Polkinghorne KR, Kerr PG, Hawley CM, Agar JW, McDonald SP.

Am J Kidney Dis. 2016 Apr;67(4):617-28. doi: 10.1053/j.ajkd.2015.09.025. Epub 2015 Nov 11.

PMID:
26561355
10.

Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.

Cho Y, Büchel J, Steppan S, Passlick-Deetjen J, Hawley CM, Dimeski G, Clarke M, Johnson DW; balANZ Trial Investigators.

Perit Dial Int. 2016 3-4;36(2):146-153. Epub 2015 Oct 1.

PMID:
26429421
11.

End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.

Mallett A, Tang W, Hart G, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Campbell SB, Clayton PA, Johnson DW.

Am J Nephrol. 2015;42(3):177-84. doi: 10.1159/000440815. Epub 2015 Sep 30.

PMID:
26418732
12.

Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.

Zhang L, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, De Zoysa J, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW.

Nephrology (Carlton). 2016 May;21(5):387-96. doi: 10.1111/nep.12629.

PMID:
26393772
13.

Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis.

Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Winkelmayer WC, van Biesen W, Crowe S, Kerr PG, Polkinghorne KR, Howard K, Pollock C, Hawley CM, Johnson DW, McDonald SP, Gallagher MP, Urquhart-Secord R, Craig JC; SONG-HD Collaboration.

Trials. 2015 Aug 19;16:364. doi: 10.1186/s13063-015-0895-7.

14.

Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group.

Can J Kidney Health Dis. 2015 Aug 18;2:33. doi: 10.1186/s40697-015-0066-5. eCollection 2015.

15.

The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW; HONEYPOT Study Collaborative Group.

Perit Dial Int. 2015 Dec;35(7):712-21. doi: 10.3747/pdi.2014.00206. Epub 2015 Jul 29.

PMID:
26224790
16.

Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED Study Team.

Nephrology (Carlton). 2016 Mar;21(3):217-28. doi: 10.1111/nep.12573.

PMID:
26205903
17.

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

Taylor E, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB, Mollee P.

Nephrol Dial Transplant. 2015 Oct;30(10):1774-9. doi: 10.1093/ndt/gfv260. Epub 2015 Jul 18.

PMID:
26188340
18.

Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease.

Krishnasamy R, Hawley CM, Stanton T, Pascoe EM, Campbell KL, Rossi M, Petchey W, Tan KS, Beetham KS, Coombes JS, Leano R, Haluska BA, Isbel NM.

BMC Nephrol. 2015 Jul 18;16:106. doi: 10.1186/s12882-015-0098-1.

19.

Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW.

Nephrol Dial Transplant. 2015 Jul 11. pii: gfv269. [Epub ahead of print] Review.

PMID:
26163881
20.

Association between left ventricular global longitudinal strain, health-related quality of life and functional capacity in chronic kidney disease patients with preserved ejection fraction.

Krishnasamy R, Hawley CM, Stanton T, Howden EJ, Beetham KS, Strand H, Leano R, Haluska BA, Coombes JS, Isbel NM.

Nephrology (Carlton). 2016 Feb;21(2):108-15. doi: 10.1111/nep.12557.

PMID:
26133896
Items per page

Supplemental Content

Loading ...
Write to the Help Desk